DKDalia Kanaa

Dalia Kanaa

*This is an algorithmically generated author record based on publicly available information.

Dalia Kanaa has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Discovery of Imine-Modified Quinazolinyl Sulfonamides as Dual hCA IX/XII Inhibitors with Potent Antiproliferative Activity

    by Hazem Essam Okda, Lingaiah Maram, Mohammad Homaidur Rahman, Andrea Ammara, Simone Giovannuzzi, Dalia Kanaa, Hannah Duggan, Mohamed Elagawany, Lamees Hegazy, Claudiu T. Supuran, et al.

    Tumor-associated carbonic anhydrases (hCA IX and XII) drive cancer survival under hypoxia. However, developing therapeutics that avoid the ubiquitous physiological isoforms (hCA I and II) to prevent off-target liabilities remains challenging. Herein, we report the design, synthesis, and evaluation of novel 3,4-dihydroquinazoline-based benzenesulfonamides as selective hCA inhibitors. Structure–activity relationship and molecular dynamics studies demonstrated that converting primary amines to imine derivatives successfully abolished hCA I activity while retaining nanomolar potency against hCA IX and XII. Specifically, BE21349 showed high affinity for hCA IX (KI = 61.8 nM) and hCA XII (KI= 40.5 nM), exhibiting over 33- and 51-fold selectivity for these respective isoforms over hCA I (KI = 2090 nM). Antiproliferative screening identified the hCA I-inactive derivatives BE21349 and BE21417 as potent multitarget agents across the NCI-60 panel. Notably, BE21417 exhibited a nearly 6-fold preference for hCA XII over hCA II, representing a promising targeted anticancer scaffold.